Analysts Set Pulmonx Corporation (NASDAQ:LUNG) PT at $6.81

Pulmonx Corporation (NASDAQ:LUNG) has been given a consensus rating of “Hold” by the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $6.8071.

Several equities research analysts have issued reports on LUNG shares. Lake Street Capital decreased their price objective on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, October 28th. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Wednesday, October 8th. Finally, D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a research note on Thursday, November 13th.

Pulmonx Stock Performance

Shares of LUNG stock opened at $2.21 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. The firm has a market capitalization of $91.16 million, a price-to-earnings ratio of -1.57 and a beta of 0.10. Pulmonx has a one year low of $1.31 and a one year high of $9.37. The company has a 50 day moving average price of $1.97 and a 200 day moving average price of $2.04.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. The company had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $20.78 million. Pulmonx had a negative net margin of 61.91% and a negative return on equity of 77.58%. Sell-side analysts anticipate that Pulmonx will post -1.55 EPS for the current year.

Hedge Funds Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently bought and sold shares of LUNG. Charles Schwab Investment Management Inc. raised its stake in shares of Pulmonx by 1.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company’s stock valued at $2,160,000 after purchasing an additional 5,414 shares during the period. Nuveen LLC acquired a new stake in Pulmonx during the 1st quarter valued at $1,336,000. Trexquant Investment LP increased its stake in Pulmonx by 140.0% during the 1st quarter. Trexquant Investment LP now owns 224,909 shares of the company’s stock worth $1,514,000 after buying an additional 131,209 shares during the period. PDT Partners LLC increased its stake in Pulmonx by 45.1% during the 1st quarter. PDT Partners LLC now owns 71,637 shares of the company’s stock worth $482,000 after buying an additional 22,259 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its holdings in Pulmonx by 194.4% in the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock worth $4,118,000 after buying an additional 404,022 shares in the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.